Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database-Reference-Cited by-同舟云学术

Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database

Published:2019-05-29 Issue:1 Volume:177 Page:185-195
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Helland Thomas,Hagen Kari Britt,Haugstøyl Martha Eimstad,Kvaløy Jan Terje,Lunde Siri,Lode Kirsten,Lind Ragna Anne,Gripsrud Birgitta Haga,Jonsdottir Kristin,Gjerde Jennifer,Bifulco Ersilia,Hustad Steinar,Jonassen Janne,Aas Turid,Lende Tone Hoel,Lien Ernst Asbjørn,Janssen Emiel Adrianus Maria,Søiland Håvard,Mellgren Gunnar^ORCID

Funder

Western Norway Health Authority

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05294-w.pdf

Reference42 articles.

1. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Nat Cancer Inst 97(22):1652–1662. https://doi.org/10.1093/jnci/dji372

2. Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B et al (2015) 14th St. Gallen International Breast Cancer Conference 2015: evidence, controversies, consensus - primary therapy of early breast cancer: opinions expressed by German experts. Breast Care 10(3):211–219. https://doi.org/10.1159/000433590

3. Davies C, Pan H, Godwin J, Gray R, Arriagada R et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816